Enzymatica AB (OSTO:ENZY) Cyclically Adjusted Revenue per Share: kr0.48 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ENZY Enzymatica AB OSTO:ENZY
58 GF Score
Price kr1.90
GF Value kr2.12
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Enzymatica AB Cyclically Adjusted Revenue per Share?

Enzymatica AB OSTO:ENZY +2.70% 58 Cyclically Adjusted Revenue per Share is kr0.48 as of Jun. 2026. GuruFocus rates OSTO:ENZY with a GF Score™ of 58/100 and a GF Value™ of kr2.12 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Enzymatica AB's adjusted revenue per share for the three months ended in Jun. 2026 was kr0.029. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr0.48 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Enzymatica AB's average Cyclically Adjusted Revenue Growth Rate was -15.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -8.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -0.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Enzymatica AB was 7.60% per year. The lowest was -8.20% per year. And the median was 1.70% per year.

As of today (2026-08-25), Enzymatica AB's current stock price is kr1.90. Enzymatica AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was kr0.48. Enzymatica AB's Cyclically Adjusted PS Ratio of today is 3.96.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Enzymatica AB was 38.97. The lowest was 2.48. And the median was 5.25.


Enzymatica AB  (OSTO:ENZY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Enzymatica AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.90/0.48
=3.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Enzymatica AB was 38.97. The lowest was 2.48. And the median was 5.25.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Enzymatica AB Cyclically Adjusted Revenue per Share Related Terms


Enzymatica AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Enzymatica AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzymatica AB Cyclically Adjusted Revenue per Share Chart

Enzymatica AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.57 0.66 0.66 0.60 0.51

Enzymatica AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.54 0.51 0.48 0.48

OSTO:ENZY vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Enzymatica AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzymatica AB Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enzymatica AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Enzymatica AB's Cyclically Adjusted PS Ratio falls into.


OSTO:ENZY
58GF Score
Enzymatica AB OSTO:ENZY
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enzymatica AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Enzymatica AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.029/134.6100*134.6100
=0.029

Current CPI (Jun. 2026) = 134.6100.

Enzymatica AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.135 101.138 0.180
201612 0.112 102.022 0.148
201703 0.095 102.022 0.125
201706 0.058 102.752 0.076
201709 0.246 103.279 0.321
201712 0.212 103.793 0.275
201803 0.153 103.962 0.198
201806 0.054 104.875 0.069
201809 0.135 105.679 0.172
201812 0.162 105.912 0.206
201903 0.086 105.886 0.109
201906 0.041 106.742 0.052
201909 0.126 107.214 0.158
201912 0.143 107.766 0.179
202003 0.173 106.563 0.219
202006 0.090 107.498 0.113
202009 0.183 107.635 0.229
202012 0.274 108.296 0.341
202103 0.110 108.360 0.137
202106 0.039 108.928 0.048
202109 0.095 110.338 0.116
202112 0.116 112.486 0.139
202203 0.026 114.825 0.030
202206 0.060 118.384 0.068
202209 0.111 122.296 0.122
202212 0.094 126.365 0.100
202303 0.073 127.042 0.077
202306 0.049 129.407 0.051
202309 0.075 130.224 0.078
202312 0.089 131.912 0.091
202403 0.052 132.205 0.053
202406 0.034 132.716 0.034
202409 0.067 132.304 0.068
202412 0.071 132.987 0.072
202503 0.051 132.825 0.052
202506 0.034 133.699 0.034
202509 0.062 133.480 0.063
202512 0.076 133.390 0.077
202603 0.047 133.560 0.047
202606 0.029 134.610 0.029

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr0.48 mean?
Enzymatica AB (OSTO:ENZY) has a Cyclically Adjusted Revenue per Share of kr0.48 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Enzymatica AB and its competitors.
Is Enzymatica AB's Cyclically Adjusted Revenue per Share too high?
Enzymatica AB's current Cyclically Adjusted Revenue per Share is kr0.48. Overall, Enzymatica AB has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's Cyclically Adjusted Revenue per Share compare to ZTS?
Enzymatica AB's Cyclically Adjusted Revenue per Share of kr0.48 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Enzymatica AB and its competitors. Enzymatica AB's current Cyclically Adjusted Revenue per Share is kr0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Based on GuruFocus' analysis, Enzymatica AB (OSTO:ENZY) is currently considered Modestly Undervalued. The stock's GF Value™ is kr2.12, compared to a current price of kr1.90 — trading 10.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr0.48. Enzymatica AB's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Enzymatica AB (OSTO:ENZY), the current Cyclically Adjusted Revenue per Share is kr0.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enzymatica AB (OSTO:ENZY) Overvalued in 2026?

Based on GuruFocus' analysis, Enzymatica AB stock appears to be undervalued. The current stock price of kr1.90 is trading 10.4% below its estimated GF Value™ of kr2.12. GuruFocus considers Enzymatica AB to be Modestly Undervalued.

Key valuation signals for OSTO:ENZY:

  • Cyclically Adjusted Revenue per Share: kr0.48
  • GF Value™: kr2.12 vs. price of kr1.90 (10.4% below fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the OSTO:ENZY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Enzymatica AB Business Description

Other Exchanges EN9:Germany
Address Scheelevagen 19, Delta 5, Ideon Science Park, Lund, SWE, SE-223 70
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
58GF Score

Get the complete analysis for OSTO:ENZY

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.90
Price
kr2.12
GF Value